After 17 years of work, Argos Therapeutics Inc. hopes to present a breakthrough in 2017 with Phase III data for its lead candidate in metastatic renal cell carcinoma – what CEO Jeff Abbey says will be precision immunotherapy that eventually could be applied broadly across the oncology space.
During an investor day presentation Dec. 7, the Durham, N.C.-based biotech outlined the clinical development process for AGS-003 (now called...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

